956199-27-2

Basic information

• Product Name: 1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine
• Synonyms: 1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine
• CAS NO: 956199-27-2
• Molecular Weight: 263.77
• Mol File: 956199-27-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine(956199-27-2)
• EPA Substance Registry System: 1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine(956199-27-2)

Safety Data

• Hazardous Substances Data: 956199-27-2(Hazardous Substances Data)

Usage

Description

1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine is a chemical compound with the molecular formula C16H20ClN3. It is a pyrazole derivative featuring a methylamino group attached to the nitrogen atom, known for its unique chemical structure and potential medicinal properties.

Uses

Used in Pharmaceutical Research:
1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine is used as a research chemical for the development of new drugs targeting specific biological pathways or receptors in the body. Its unique structure makes it a promising candidate for creating novel therapeutic agents.
Used in Chemical Synthesis:
1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine is also used as a pharmaceutical intermediate, playing a crucial role in the synthesis of more complex molecules with potential medicinal applications.
Used in Academic and Industrial Research:
The potential of 1-(1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine as a ligand for metal complexes or catalysts is of interest for further research in both academic and industrial settings. Its ability to form stable complexes with metals could lead to advancements in various chemical processes.
Further studies are necessary to fully understand the potential uses and effects of this chemical compound, as its applications may extend beyond the current understanding.

Upstream product

• 611-19-8 1-chloro-2-(chloromethyl)benzene 
• 67-51-6 3,5-dimethyl-1H-pyrazole 
• 908228-44-4 1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazole 
• 593-51-1 methylamine hydrochloride 
• 50-00-0 formaldehyd 

Downstream Products

• 956507-49-6 1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl) (methyl)amino)-3-(4-ethoxyphenoxy)propan-2-ol 
• 1311146-81-2 1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol 
• 1227743-93-2 (S)-1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-ethoxyphenoxy)propan-2-ol 
• 1227743-94-3 (R)-1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-ethoxyphenoxy)propan-2-ol 
• 1280193-99-8 N-((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-methyl)-3-(4-ethoxyphenoxy)-2-methoxy-N-methylpropan-1-amine 
• 1311146-80-1 1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(3,4-dichlorophenoxy)propan-2-ol 
• 1280194-02-6 1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-phenoxypropan-2-ol 
• 1280193-92-1 (S)-1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-chlorophenoxy)propan-2-ol 
• 1311146-79-8 (R)-1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-chlorophenoxy)propan-2-ol 

Relevant articles and documents

Carbazole beta-alkamine derivatives, and pharmaceutical composition, preparation method and application thereof

The invention relates to carbazole beta-alkamine derivatives, and a pharmaceutical composition, preparation method and application thereof. The compounds disclosed by the invention can effectively inhibit the activity and level of a toll-like receptor 4 a

Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents

Toll-like receptor 4 (TLR4) initiates innate immune response to release inflammatory cytokines and has been pathologically linked to variety of inflammatory diseases. Recently, we found that Carvedilol, as the classic anti-heart failure and anti-inflammatory clinic drug, could inhibit the TLR4 signaling in the TLR4 overexpressed cells. Herein, we have designed and synthesized a small library of novel Carvedilol derivatives and investigated their potential inhibitory activity. The results indicate that the most potent compound 8a (SMU-XY3) could effectively inhibited TLR4 protein and the LPS triggered alkaline phosphatase signaling in HEK-Blue hTLR4 cells. It down regulated the nitric oxide (NO) in both RAW264.7 cells and BV-2 microglial cells, in addition to blocking the TNF-α signaling in ex-vivo human peripheral blood mononuclear cells (PBMC). More interestingly, 8a shows higher affinity to hyperpolarization-activated cyclic nucleotide-gated 4 (HCN4) over HCN2, which probably indicates the new application of TLR4 inhibitor 8a in heart failure, coronary heart disease, and other inflammatory diseases.

Development of β-amino alcohol derivatives that inhibit toll-like receptor 4 mediated inflammatory response as potential antiseptics

Toll-like receptor 4 (TLR4) induced proinflammatory signaling has been directly implicated in severe sepsis and represents an attractive therapeutic target. Herein, we report our investigations into the structure-activity relationship and preliminary drug metabolism/pharmacokinetics study of β-amino alcohol derivatives that inhibit the TLR4 signaling pathway. Lead compounds were identified from in vitro cellular examination with micromolar potency for their inhibitory effects on TLR4 signaling and subsequently assessed for their ability to suppress the TLR4-induced inflammatory response in an ex vivo whole blood model. In addition, the toxicology, specificity, solubility, brain-blood barrier permeability, and drug metabolism of several compounds were evaluated. Although further optimizations are needed, our findings lay the groundwork for the future drug development of this class of small molecule agents for the treatment of severe sepsis.